| Autor: | José Melena, John P. M. Wood, Neville N. Osborne, Glyn Chidlow, Louis Desantis |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Retina
medicine.medical_specialty Intraocular pressure genetic structures business.industry Glaucoma medicine.disease Glaucomatous optic neuropathy Neuroprotection Retinal ganglion eye diseases Ganglion Ophthalmology medicine.anatomical_structure medicine Optometry sense organs Animal studies business |
| Zdroj: | Ophthalmology Clinics of North America. 13:123-130 |
| ISSN: | 0896-1549 |
| DOI: | 10.1016/s0896-1549(05)70171-1 |
| Popis: | Currently, glaucoma therapy is directed at lowering intraocular pressure (IOP) primarily by pharmacologic means and to a lesser extent by surgery. 2,16,45 Although raised IOP can undoubtedly cause dysfunction to retinal ganglion cells and loss of vision, as in glaucoma, it is not likely to be the major cause for glaucomatous visual loss in every patient. 35 Nevertheless, lowering IOP is presently the only way of treating glaucoma in the clinic. As this millennium draws to a close, however, the inadequacies of this method are increasingly being recognized. The goal for the future must, therefore, be to discover a therapy that preserves visual function irrespective of the cause of glaucomatous optic neuropathy. One possibility is for a drug to interact with intraretinal components to somehow attenuate whatever it is that causes visual field loss in glaucoma. This approach has been termed neuroprotection in glaucoma. 6,21,24,30,33,35 It is known from animal studies that topically applied drugs can reach the retina and other ocular tissues by way of both local and systemic routes. 33,34,35,36 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|